Interestingly, Tieszen et al. investigated the potential of PR antagonists, to inhibit the growth of cells from endocrine related cancers (i.e. ovarian-, breast-, and prostate cancer cells), expressing different sets of hormone receptors. This evidence concerns the gene PGR and Familial prostate cancer.